Hematologic Cancer
36
10
12
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.8%
1 terminated out of 36 trials
90.0%
+3.5% vs benchmark
3%
1 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (36)
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer
The Florida ASCENT Study
Rutgers University Study of the Genetics of Blood Cancers
Improving Comprehensive Care of Cancer Patients
The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Intervention for Fatigue in HCT Recipients
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Avera Cancer Sequencing and Analytics Protocol (ASAP)
The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating
Discontinuation Study
Coverage and Cost of Care Links- Telehealth
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
Precision Physical Exercise for Personalized Onco-Hematology.
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
Hypnosis: a Path to Appeasement
Symptom Management for YA Cancer Survivors
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Improving Patient Experience: BMBA